Company TScan Therapeutics, Inc.

Equities

TCRX

US89854M1018

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for TScan Therapeutics, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 26/06/2024 am IST			5-day change	1st Jan Change
6.19 ^USD	-7.47%		-10.81%	+6.17%

17/06	Certain Pre-Funded Warrants of TScan Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 17-JUN-2024.	CI
17/06	Certain Stock Options of TScan Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 17-JUN-2024.	CI

TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Companyâs lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, a collection of solid tumor targets across different Human leukocyte antigens (HLAs) types in the TCR field. The Company is advancing approximately six solid tumor programs: TSC-204, TSC-200, TSC-203, TSC-201, TSC-202 and TSC-205.

Number of employees: 164

USD in Million	2022	Weight	2023	Weight	Delta
T Cell Receptor-engineered T Cell 100.0 %	14	100.0 %	21	100.0 %	+55.52%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	14	100.0 %	21	100.0 %	+55.52%

Managers	Title	Age	Since
Gavin MacBeath CEO	Chief Executive Officer	54	01/18/01
Jason Amello DFI	Director of Finance/CFO	55	29/01
Justin McCue CTO	Chief Tech/Sci/R&D Officer	-	04/12
Ray Lockard CTO	Chief Tech/Sci/R&D Officer	-	06/23/06
Shrikanta Chattopadhya CTO	Chief Tech/Sci/R&D Officer	-	-
Heather Savelle IRC	Investor Relations Contact	-	05/21/05
Leiden Dworak AUD	Comptroller/Controller/Auditor	-	11/22/11
Zoran Zdraveski LAW	General Counsel	54	09/21/09
Ann Hargraves HRO	Human Resources Officer	-	01/20/01

Members of the board	Title	Age	Since
Stephen Biggar CHM	Chairman	53	01/21/01
Gavin MacBeath CEO	Chief Executive Officer	54	01/18/01
Barbara Klencke BRD	Director/Board Member	66	06/23/06
Katina Dorton BRD	Director/Board Member	66	23/21/23
R. Woods BRD	Director/Board Member	56	06/12
Gabriela Gruia BRD	Director/Board Member	67	27/21/27

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	4,276,588	0	0	91.12 %
Stock B	1	48,586,217	48,166,302 ( 99.14 %)	0

Name	Equities	%	Valuation
Lynx1 Capital Management LP 10.75 %	5,224,600	10.75 %	45 M $
Lynx1 Capital Management LP 10.75 %	5,224,600	10.75 %	45 M $
EcoR1 Capital, LLC 10.29 %	5,000,000	10.29 %	43 M $
Adage Capital Partners GP LLC 8.027 %	3,900,000	8.027 %	33 M $
BVF, Inc. 6.153 %	2,989,474	6.153 %	26 M $
Baker Bros. Advisors LP 5.732 %	2,784,792	5.732 %	24 M $
Baker Bros. Advisors LP 5.732 %	2,784,792	5.732 %	24 M $
Cormorant Asset Management LP 5.145 %	2,500,000	5.145 %	21 M $
K2 Healthventures Equity Trust LLC 4.501 %	2,186,854	4.501 %	19 M $
Propel Bio Management LLC 4.296 %	2,087,139	4.296 %	18 M $

Name	Equities	%	Valuation
Baker Bros. Advisors LP 42.77 %	4,276,588	42.77 %	37 M $

TScan Therapeutics, Inc.

830 Winter Street

02451, Waltham

http://www.tscan.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.19 USD

Average target price

12.29 USD

Spread / Average Target

+98.48%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
TSCAN THERAPEUTICS, INC.	+6.17%	33Cr
MODERNA, INC.	+38.36%	5.27TCr
LONZA GROUP AG	+36.73%	3.9TCr
IQVIA HOLDINGS INC.	-8.63%	3.85TCr
ALNYLAM PHARMACEUTICALS, INC.	+25.46%	3.04TCr
CELLTRION, INC.	-11.17%	2.64TCr
ICON PUBLIC LIMITED COMPANY	+11.44%	2.61TCr
UNITED THERAPEUTICS CORPORATION	+45.09%	1.42TCr
MEDPACE HOLDINGS, INC.	+32.93%	1.26TCr
BIO-TECHNE CORPORATION	-5.30%	1.15TCr

Other Biotechnology & Medical Research